$2.97
-0.03 (-1.00%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where ALT is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
18 interventional · 1 observational · 5 with posted results
Held by 14 tracked-famous managers (MARSHALL WACE, LLP, VIKING GLOBAL INVESTORS LP, MILLENNIUM MANAGEMENT LLC, TWO SIGMA INVESTMENTS, LP, AQR CAPITAL MANAGEMENT LLC, +9 more) · FINRA short interest 11.4 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| RESTORE TRIAL: Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD)NCT07009860Relative (%) reduction in liver stiffness by VCTE compared to baselineRandomized · Quadruple-masked · Treatment | Phase 2 | Active, not recruiting | Drug: Pemvidutide · Other: Placebo | Alcohol-associated Liver Disease | 121 | 2027-09-30 | in 407 d | 2026-08-17 |
| RECLAIM STUDY: Phase 2 Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or OverweightNCT06987513Change from baseline in the average number of heavy drinking days per weekRandomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: Pemvidutide · Other: Placebo | Alcohol Use Disorder (AUD) | 100 | 2026-07-30actual | — | 2026-07-31 |
| IMPACT TRIAL: Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH)NCT05989711Proportion of subjects achieving NASH resolution (NAFLD activity score [NAS], ballooning = 0; lobular inflammation = 0, 1) with at least a 2-point reduction in NAS without worsening of fibrosisRandomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: Pemvidutide, Placebo | Non-Alcoholic Steatohepatitis (NASH) | 212 | 2025-11-25actual | — | 2026-05-18 |
| HepTcell Immunotherapy in Patients With Inactive Chronic Hepatitis B (CHB)NCT04684914results2025-12-08The Proportion of Patients Achieving Virologic ResponsesRandomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Did not meet endpoints | Biological: HepTcell · Drug: Placebo | Hepatitis B, Chronic | 87 | 2024-03-27actual | — | 2025-12-08 |
| Efficacy and Safety of ALT-801 in the Treatment of ObesityNCT05295875Relative change from baseline in body weight percentageRandomized · Double-masked · Treatment | Phase 2 | Completed | Drug: ALT-801 · Other: Placebo | Obesity/Overweight | 391 | 2023-09-28actual | — | 2023-11-29 |
| ALT-801 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus (T2DM)NCT05134662The Number of Participants with One or More Treatment-Emergent Adverse Events (TEAEs)Randomized · Double-masked · Treatment | Phase 1 | Completed | Drug: ALT-801 · Other: Placebo | Type 2 Diabetes | 55 | 2023-02-03actual | — | 2025-06-24 |
| Extension of ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With (NAFLD)NCT05292911The Number of Participants with One or More Treatment-Emergent Adverse Events (TEAEs)Randomized · Double-masked · Treatment | Phase 1 | Completed | Drug: ALT-801 · Other: Placebo | Non-Alcoholic Fatty Liver Disease | 64 | 2022-10-31actual | — | 2023-07-27 |
| ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD)NCT05006885The Number of Participants with One or More Treatment-Emergent Adverse Events (TEAEs)Randomized · Double-masked · Treatment | Phase 1 | Completed | Drug: ALT-801 · Other: Placebo | Non-Alcoholic Fatty Liver Disease | 95 | 2022-08-17actual | — | 2023-07-27 |
| Pemvidutide (ALT-801) DDI Study in Healthy VolunteersNCT04972396Area Under the Plasma Concentration Versus Time Curve (AUC) of metformin and atorvastatin/warfarin and digoxin in presence of steady state ALT-801Randomized · Open-label · Other | Phase 1 | Completed | Drug: Pemvidutide, Metformin, Atorvastatin, Warfarin, Digoxin, Ethinylestradiol and Levonorgestrel | NASH - Nonalcoholic Steatohepatitis | 40 | 2022-05-15actual | — | 2025-06-24 |
| Safety and Immunogenicity of AdCOVID in Healthy Adults (COVID-19 Vaccine Study)NCT04679909ReactogenicityRandomized · Double-masked · Prevention | Phase 1 | Completed | Biological: AdCOVID · Other: Placebo | Healthy Volunteers | 92 | 2021-12-01actual | — | 2023-08-14 |
| ALT-801 (Pemvidutide) in Healthy Overweight and Obese Volunteers to Study Safety and TolerabilityNCT04561245The Number of Participants with One or More Treatment-Emergent Adverse Events (TEAEs)Randomized · Double-masked · Treatment | Phase 1 | Completed | Drug: ALT-801 · Other: Placebo | Obesity, Nonalcoholic Steatohepatitis | 100 | 2021-10-29actual | — | 2025-06-24 |
| NasoShield in Healthy Adults to Study Safety and ImmunogenicityNCT04415749Reactogenicity to evaluate the safety of NasoShieldRandomized · Double-masked · Prevention | Phase 1 | Completed | Biological: NasoShield · Other: Placebo | Healthy Volunteers | 43 | 2021-03-15actual | — | 2025-06-24 |
| NasoVAX in Patients With Early Coronavirus Infectious Disease 2019 (COVID-19)NCT04442230results2022-04-04Percentage of Patients With Clinical WorseningRandomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Enrollment | Biological: NasoVAX · Other: Placebo | Coronavirus Infection | 48 | 2021-02-15actual | — | 2022-04-04 |
| NasoShield Study of Safety and ImmunogenicityNCT03352466ReactogenicityRandomized · Double-masked · Prevention | Phase 1 | Completed | Biological: NasoShield, BioThrax · Other: Placebo | Healthy Volunteers | 145 | 2019-05-13actual | — | 2025-06-24 |
| Study of the Safety and Immunogenicity of NasoVAX ExtensionNCT03760549observationalImmune response to NasoVAX when administered by intranasal spray at a single dose of 1×10(11th) vp after approximately 1year | — | Completed | Drug: Subjects were administered NasoVAX high dose | Influenza | 8 | 2019-02-18actual | — | 2025-06-19 |
| Single-ascending-dose Study of the Safety and Immunogenicity of NasoVAXNCT03232567results2019-04-11Number of Treatment-Emergent Adverse Events in Participants [Safety and Tolerability]Randomized · Triple-masked · PreventionStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Biological: NasoVAX | Influenza | 60 | 2018-03-07actual | — | 2024-04-30 |
| Immune Response Following Seasonal Influenza VaccinationNCT03163342results2019-04-26HAI Antibody Immune Response to Matched Influenza Strain H1N1 A/California/04/2009 StrainOpen-label · DiagnosticStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 4 | Completed | Biological: Licensed seasonal influenza vaccine | Influenza | 20 | 2017-11-21actual | — | 2019-04-26 |
| Phase I Safety and Immunogenicity of FP-02.2 in Chronic Hepatitis BNCT02496897results2025-05-22Number of Subjects With Treatment Emergent Adverse Events (TEAEs)Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Biological: FP-02.2 Vaccine · Other: Placebo, IC31® Adjuvant | Hepatitis B | 61 | 2017-10-13actual | — | 2025-05-22 |
| Safety and Immunogenicity Study of Adenovirus-vectored, Intranasal Pandemic Influenza Vaccine.NCT00755703To assess the safety of a nasally administered adenovirus-vectored pandemic influenza vaccine in healthy human adults.Randomized · Quadruple-masked · Prevention | Phase 1 | Completed | Biological: Pandemic Influenza Vaccine, Placebo | Influenza A Subtype H5N1 Infection | 48 | Sep 2009actual | — | 2025-05-29 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19